title: Management of symptomatic bone metastases from breast cancer with concomitant use of external radiotherapy and ibandronate: results of a prospective, pilot study.
authors.forename: Vassilios
authors.initials: V
authors.lastname: Vassiliou
authors.forename: Christine
authors.initials: C
authors.lastname: Kalogeropoulou
authors.forename: Leotsinidis
authors.initials: L
authors.lastname: Mihael
authors.forename: Athanassios
authors.initials: A
authors.lastname: Tsamandas
authors.forename: Theodoros
authors.initials: T
authors.lastname: Petsas
authors.forename: Efstathia
authors.initials: E
authors.lastname: Giannopoulou
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kardamakis
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077557:Ibandronic Acid; D009367:Neoplasm Staging; D010147:Pain Measurement; D010865:Pilot Projects; D011336:Probability; D011446:Prospective Studies; D011788:Quality of Life; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid